Updates

Tweets by @CellCentric

All our updates and events through tweets

As we develop our new cancer drug, inobrodib, we listen to patients. Having an oral product that can be taken at home, reducing time spent at hospital, is a big differentiator. pic.twitter.com/DBQfrnrzW9

CellCentric presenting at #ASH22. Exciting Phase I data treating RR multiple myeloma, and other haems. Inobrodib: small molecule p300/CBP inhibitor. cellcentric.com/updates/press-… pic.twitter.com/FW3mgZqwx7

Kris and Neil at #PCFRetreat22 Carlsbad CA, meeting our international clinical collaborators. Inobrodib being trialled to treat mCRPC. pic.twitter.com/8KSTk2MI8v

Stay up to date with CellCentric and follow us on twitter

Follow us

CellCentric will be attending the International Myeloma Society - FDA joint meeting, 8-9 Nov. The future of MM drug development. pic.twitter.com/oCWBtO7VCv

It’s #PCFRetreat22. Neil & Kris from CellCentric attending. Inobrodib, first in class p300/CBP inhibitor, in phase II mCRPC clinical trials. pic.twitter.com/35HI5oozKU

Team at @SygnatureDiscov today, our excellent long term partners. Talk: From Molecule to Medicine. Inobrodib, making a difference to people with cancer. pic.twitter.com/kxLGW6YJT4